Cutaneous melanoma remains the most lethal of the primary cutaneous neoplasms, and
although the incidence of primary melanoma continues to rise, the mortality from metastatic …

Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …

Background Extensive-stage small-cell lung cancer (ES-SCLC) is associated with poor
prognosis and treatment options are scarce. Immunotherapy has shown robust clinical …

Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …

Pancreatic adenocarcinoma remains one of the most lethal cancers globally, with a
significant need for improved therapeutic options. While the recent breakthroughs of …

Immunotherapy has become an important part of the oncotherapy arsenal. Its applicability in
various cancer types is impressive, as well as its use of endogenous mechanisms to achieve …

Liver cancer, specifically hepatocellular carcinoma (HCC), is the sixth most common cancer
and the third leading cause of cancer mortality worldwide. The development of effective …

Natural killer (NK) cells recognize and kill target cells undergoing different types of stress.
NK cells are also capable of modulating immune responses. In particular, they regulate T …

Immune checkpoint inhibitors have revolutionised cancer treatment by offering durable
responses to many patients with solid and haematological cancers. The high prices and …

Background Immune-related adverse events (irAEs) are a common phenomenon in cancer
patients treated with immune checkpoint inhibitors (ICIs). Surprisingly, the toxicity burdens of …